Matte Beauty
FDA issued a warning letter to Matte Beauty (Destin, FL, United States) on Jul 25, 2024. Subject: Finished Pharmaceuticals, Unapproved New Drugs.
From the letter: “your chemical peels are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (the “FD&C Act”), 21 U.S.C. 355(a) and…”
At a glance
What a reviewer notes before reading: findings, citations, the response deadline and what the letter warns of.
- Violations
- 11 findings · 2 issue types
- Cited
- No CFR or ISO section
- Response due
- 15 working days after receipt of this letter
- FDA asks for
- 4 actions
- Named as possible actions
- Seizure, injunction
- Issued by
- Center for Drug Evaluation and Research
- Published status
- No close-out recorded
AI assisted findings
Model-assisted reading of each issue. Open one to see the FDA text it comes from, and check it against the full letter.
01Registration, listing & premarketChemical peels are unapproved new drugs introduced into interstate commerce without approved applications.
your chemical peels are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (the “FD&C Act”), 21 U.S.C. 355(a) and 331(d).
02Labeling, claims & marketingChemical peels are drugs because they are intended to treat or prevent disease or affect body structure/function.
your firm’s chemical peels are drugs as defined by section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or intended to affect the structure or any function of the body.
03Labeling, claims & marketingWebsite claims establish intended use for treating skin conditions and aging.
“KEY BENEFITS AND INGREDIENTS . . . o [R]educe scars, wrinkles, fine lines, acne & reverse the visible signs of aging. o Stimulates development of new collagen and elastin fibroblasts o Reduces sebaceous follicle blockage, unclogs pores, and kills bacteria responsible for acne . . . o TCA (Trichloroacetic Acid)- a powerful exfoliating agent works by removing the outer damaged layers of the skin in the epidermal and dermal regions.”
04Labeling, claims & marketingLactic acid product claims include treating hyperpigmentation and stimulating collagen.
“KEY BENEFITS AND INGREDIENTS o [E]ffectively lighten pigmentation . . . o Promotes stimulation of collagen” • “LACTIC ACID - is specifically used to treat hyperpigmentation, age spots, and other factors that contribute to a dull and uneven complexion.”
05Labeling, claims & marketingSalicylic acid product claims include treating acne and skin conditions.
“KEY BENEFITS AND INGREDIENTS . . . o Fights acne o Fades Acne Scars & Blemishes o Opens Clogged Pores o Controls all types of acne” • “TREAT MULTIPLE SKIN CONDITIONS! Salicylic Acid Peel will reduce acne inflammation and scars, sun damage, blemishes, blackheads, whiteheads, acne, psoriasis”
06Labeling, claims & marketingGlycolic acid product claims include stimulating collagen and treating acne and sun damage.
“KEY BENEFITS AND INGREDIENTS o Stimulates collagen production o Increasing cell regeneration” • “Encourages increased cell turnover” • “Reduces active acne and acne marks” • “Professional Strength for Wrinkles, Fine Lines and Sun Damage. 70% . . . is recommended for the neck, for sun damage, stretch marks, acne, scars, hyper-pigmentation, ingrown hairs.”
07Labeling, claims & marketingJessner peel product claims include reducing hyperpigmentation and treating acne and wrinkles.
“KEY BENEFITS AND INGREDIENTS o Reduces hyperpigmentation” • “[L]ighten areas of skin discoloration” • “SALICYLIC ACID 14% - salicylic acid peels . . . loosen blackheads . . . and even discoloration” • “TCA 14% - . . . Reduction of acne, clogged pores, scars, wrinkles, and fine lines. Increase in collagen and elastin production.” • “LACTIC ACID 14% - treats hyperpigmentation, age spots”
08Labeling, claims & marketingInstagram posts claim chemical peels treat skin disorders and aging.
“Why facial peel? . . . Chemical Peels also help skin disorders like acne and rosacea . . . #chemicalpeel”
09Labeling, claims & marketingInstagram posts describe chemical peels as treating wrinkles, acne, and uneven skin tone.
“A chemical peel is a skin-resurfacing procedure . . . A light (superficial) chemical peel removes the outer layer of skin (epidermis). It’s used to treat fine wrinkles, acne, uneven skin tone and dryness . . . A medium chemical peel removes skin cells from the epidermis and from portions of the upper part of your middle layer of skin (dermis). It’s used to treat wrinkles, acne scars and uneven skin tone.”
10Labeling, claims & marketingInstagram post claims acids increase collagen production.
“[A]cids lift away dead cells . . . As the topmost layer is shed, signals are sent to the living cells below to multiply and move up, to increase collagen production, to make more hyaluronic acid”
11Registration, listing & premarketProducts are not generally recognized as safe and effective, making them new drugs without approved applications.
Your chemical peels are not generally recognized as safe and effective for the above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355 are in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).
What FDA requested
- Notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct these violations.
- Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation.
- If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.
- If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.
FDA Warning Letter
23 paragraphs · 3 sectionsText as published on FDA.gov, retrieved Sep 8, 2026. Layout added for reading; the wording is FDA’s. View on FDA.gov (opens in a new tab)
1Introduction
2 paragraphs
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https://www.mattebeauty.co/ in March and April 2024 and has observed that your website offers numerous chemical peel drug products1, including “TCA 100% Skin Peel,” “Lactic Acid 90%,” “Salicylic Acid 80%,” “Glycolic Acid 70%,” and “Modified Jessner Solution Peel 14%,” (hereinafter referred to as your “chemical peels”) for sale in the United States. We have also reviewed your social media website at https://www.instagram.com/mattebeauty.co, which directs consumers to your above-mentioned website to purchase your products. As described below, your chemical peels are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (the “FD&C Act”), 21 U.S.C. 355(a) and 331(d).
The Agency is concerned about potent chemical peel products that are available to be purchased and used by consumers. Such products pose a public health risk because they can cause skin injuries such as burns on the area of application, wounds, pain, swelling, and scarring. FDA has received adverse event reports of injuries involving use of such products, some of which required emergency room care, specialty care from a dermatologist, and/or surgical intervention.
2Unapproved New Drugs
8 paragraphs
Based on a review of your websites, your firm’s chemical peels are drugs as defined by section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or intended to affect the structure or any function of the body. Examples of claims2 observed on your websites for your chemical peels that establish the intended use of these products as drugs include, but may not be limited to, the following:
From the product pages for your “Trichloroacetic Acid (TCA) Skin Peels” on your website https://www.mattebeauty.co/tca: • “KEY BENEFITS AND INGREDIENTS . . . o [R]educe scars, wrinkles, fine lines, acne & reverse the visible signs of aging. o Stimulates development of new collagen and elastin fibroblasts o Reduces sebaceous follicle blockage, unclogs pores, and kills bacteria responsible for acne . . . o TCA (Trichloroacetic Acid)- a powerful exfoliating agent works by removing the outer damaged layers of the skin in the epidermal and dermal regions.”
From the product pages for your “Lactic Acid Skin Peels” on your website https://www.mattebeauty.co/lactic-acid: • “KEY BENEFITS AND INGREDIENTS o [E]ffectively lighten pigmentation . . . o Promotes stimulation of collagen” • “LACTIC ACID - is specifically used to treat hyperpigmentation, age spots, and other factors that contribute to a dull and uneven complexion.”
From the product pages for your “Salicylic Acid Skin Peels” on your website https://www.mattebeauty.co/salicylic-acid: • “KEY BENEFITS AND INGREDIENTS . . . o Fights acne o Fades Acne Scars & Blemishes o Opens Clogged Pores o Controls all types of acne” • “TREAT MULTIPLE SKIN CONDITIONS! Salicylic Acid Peel will reduce acne inflammation and scars, sun damage, blemishes, blackheads, whiteheads, acne, psoriasis”
From the product pages for your “Glycolic Acid Skin Peels” on your website https://www.mattebeauty.co/shop: • “KEY BENEFITS AND INGREDIENTS o Stimulates collagen production o Increasing cell regeneration” • “Encourages increased cell turnover” • “Reduces active acne and acne marks” • “Professional Strength for Wrinkles, Fine Lines and Sun Damage. 70% . . . is recommended for the neck, for sun damage, stretch marks, acne, scars, hyper-pigmentation, ingrown hairs.”
From the product pages for your “Jessner Skin Peels” on your website https://www.mattebeauty.co/jessner-peel: • “KEY BENEFITS AND INGREDIENTS o Reduces hyperpigmentation” • “[L]ighten areas of skin discoloration” • “SALICYLIC ACID 14% - salicylic acid peels . . . loosen blackheads . . . and even discoloration” • “TCA 14% - . . . Reduction of acne, clogged pores, scars, wrinkles, and fine lines. Increase in collagen and elastin production.” • “LACTIC ACID 14% - treats hyperpigmentation, age spots”
From your Instagram social media website https://www.instagram.com/mattebeauty.co: • August 29, 2023 posting: o “Why facial peel? . . . Chemical Peels also help skin disorders like acne and rosacea . . . #chemicalpeel” • June 30, 2023 posting: o “A chemical peel is a skin-resurfacing procedure . . . A light (superficial) chemical peel removes the outer layer of skin (epidermis). It’s used to treat fine wrinkles, acne, uneven skin tone and dryness . . . A medium chemical peel removes skin cells from the epidermis and from portions of the upper part of your middle layer of skin (dermis). It’s used to treat wrinkles, acne scars and uneven skin tone.” • March 20, 2022 posting: o “[A]cids lift away dead cells . . . As the topmost layer is shed, signals are sent to the living cells below to multiply and move up, to increase collagen production, to make more hyaluronic acid”
Your chemical peels are not generally recognized as safe and effective for the above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355 are in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).
3Conclusion
3 paragraphs
This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.
This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction. Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.
Your response should be sent to U.S. Food and Drug Administration, CDER/OC/Office of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov.
Citations and trends
Each 21 CFR section, ISO 13485 clause and issue type in this letter, how often it appears across all letters, and its trend by the year FDA issued the letters. 2026 runs to Nov 3, 2026, compared with the same dates last year. Select a row or a bar to see those letters in Letters. As cited in this historical letter, not a statement of current requirements.
This letter cites no 21 CFR section or ISO 13485 clause.
Issue types
Record details
- Issuing center
- Center for Drug Evaluation and Research
- Issuing office
- Center for Drug Evaluation and Research
- Location
- Destin, FL, United States
- Letter posted date
- Jul 30, 2024
- Letter issue date
- Jul 25, 2024
- Addressed to
- CEO
- Inspection dates
- Not recorded
- Response window
- 15 working days after receipt of this letter
Read the source clause
Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct these violations.
- Record length
- 1,332 words · 0 recorded redactions
- Published status
- No published close-out
- Original letter
- View on FDA.gov (opens in a new tab)
- Dataset last checked
- Nov 11, 2026 · How this is built
A response window is not a calculated due date. Source excerpts are selected passages. Finding interpretations and categories are model-assisted. Verify the original letter before relying on a finding.